vs

Side-by-side financial comparison of BOK FINANCIAL CORP (BOKF) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Royalty Pharma plc is the larger business by last-quarter revenue ($622.0M vs $589.6M, roughly 1.1× BOK FINANCIAL CORP). Royalty Pharma plc runs the higher net margin — 34.4% vs 30.1%, a 4.4% gap on every dollar of revenue. On growth, BOK FINANCIAL CORP posted the faster year-over-year revenue change (12.7% vs 4.8%). Over the past eight quarters, BOK FINANCIAL CORP's revenue compounded faster (13.8% CAGR vs 4.6%).

BOK Financial Corporation — pronounced as letters, "B-O-K" — is a financial services holding company headquartered in Tulsa, Oklahoma. Offering a full complement of retail and commercial banking products and services across the American Midwest and Southwest, the company is one of the 50 largest financial services firms in the U.S., and the largest in Oklahoma.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

BOKF vs RPRX — Head-to-Head

Bigger by revenue
RPRX
RPRX
1.1× larger
RPRX
$622.0M
$589.6M
BOKF
Growing faster (revenue YoY)
BOKF
BOKF
+7.9% gap
BOKF
12.7%
4.8%
RPRX
Higher net margin
RPRX
RPRX
4.4% more per $
RPRX
34.4%
30.1%
BOKF
Faster 2-yr revenue CAGR
BOKF
BOKF
Annualised
BOKF
13.8%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BOKF
BOKF
RPRX
RPRX
Revenue
$589.6M
$622.0M
Net Profit
$177.3M
$214.2M
Gross Margin
Operating Margin
38.8%
62.4%
Net Margin
30.1%
34.4%
Revenue YoY
12.7%
4.8%
Net Profit YoY
30.2%
2.9%
EPS (diluted)
$2.90
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BOKF
BOKF
RPRX
RPRX
Q4 25
$589.6M
$622.0M
Q3 25
$548.4M
$609.3M
Q2 25
$535.3M
$578.7M
Q1 25
$502.3M
$568.2M
Q4 24
$523.1M
$593.6M
Q3 24
$516.3M
$564.7M
Q2 24
$555.7M
$537.3M
Q1 24
$455.3M
$568.0M
Net Profit
BOKF
BOKF
RPRX
RPRX
Q4 25
$177.3M
$214.2M
Q3 25
$140.9M
$288.2M
Q2 25
$140.0M
$30.2M
Q1 25
$119.8M
$238.3M
Q4 24
$136.2M
$208.2M
Q3 24
$140.0M
$544.0M
Q2 24
$163.7M
$102.0M
Q1 24
$83.7M
$4.8M
Operating Margin
BOKF
BOKF
RPRX
RPRX
Q4 25
38.8%
62.4%
Q3 25
32.2%
70.1%
Q2 25
33.8%
36.3%
Q1 25
30.8%
94.0%
Q4 24
33.5%
60.9%
Q3 24
33.6%
Q2 24
38.0%
50.2%
Q1 24
23.5%
-13.0%
Net Margin
BOKF
BOKF
RPRX
RPRX
Q4 25
30.1%
34.4%
Q3 25
25.7%
47.3%
Q2 25
26.2%
5.2%
Q1 25
23.8%
41.9%
Q4 24
26.0%
35.1%
Q3 24
27.1%
96.3%
Q2 24
29.5%
19.0%
Q1 24
18.4%
0.8%
EPS (diluted)
BOKF
BOKF
RPRX
RPRX
Q4 25
$2.90
$0.49
Q3 25
$2.22
$0.67
Q2 25
$2.19
$0.07
Q1 25
$1.86
$0.55
Q4 24
$2.13
$0.46
Q3 24
$2.18
$1.21
Q2 24
$2.54
$0.23
Q1 24
$1.29
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BOKF
BOKF
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$618.7M
Total DebtLower is stronger
$4.6B
$9.0B
Stockholders' EquityBook value
$5.9B
$9.7B
Total Assets
$52.2B
$19.6B
Debt / EquityLower = less leverage
0.78×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BOKF
BOKF
RPRX
RPRX
Q4 25
$618.7M
Q3 25
$938.9M
Q2 25
$631.9M
Q1 25
$1.1B
Q4 24
$929.0M
Q3 24
$950.1M
Q2 24
$1.8B
Q1 24
$843.0M
Total Debt
BOKF
BOKF
RPRX
RPRX
Q4 25
$4.6B
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$4.5B
$7.6B
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
BOKF
BOKF
RPRX
RPRX
Q4 25
$5.9B
$9.7B
Q3 25
$6.0B
$9.6B
Q2 25
$5.9B
$9.5B
Q1 25
$5.8B
$9.8B
Q4 24
$5.5B
$10.3B
Q3 24
$5.6B
$10.3B
Q2 24
$5.2B
$9.8B
Q1 24
$5.1B
$9.9B
Total Assets
BOKF
BOKF
RPRX
RPRX
Q4 25
$52.2B
$19.6B
Q3 25
$50.2B
$19.3B
Q2 25
$51.0B
$18.3B
Q1 25
$50.5B
$17.6B
Q4 24
$49.7B
$18.2B
Q3 24
$50.1B
$18.0B
Q2 24
$50.4B
$17.7B
Q1 24
$50.2B
$16.1B
Debt / Equity
BOKF
BOKF
RPRX
RPRX
Q4 25
0.78×
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.80×
0.74×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BOKF
BOKF
RPRX
RPRX
Operating Cash FlowLast quarter
$739.6M
$827.1M
Free Cash FlowOCF − Capex
$575.2M
FCF MarginFCF / Revenue
97.6%
Capex IntensityCapex / Revenue
27.9%
Cash ConversionOCF / Net Profit
4.17×
3.86×
TTM Free Cash FlowTrailing 4 quarters
$1.4B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BOKF
BOKF
RPRX
RPRX
Q4 25
$739.6M
$827.1M
Q3 25
$867.8M
$702.6M
Q2 25
$89.4M
$364.0M
Q1 25
$20.3M
$596.1M
Q4 24
$1.4B
$742.5M
Q3 24
$246.7M
$703.6M
Q2 24
$463.5M
$658.2M
Q1 24
$179.2M
$664.6M
Free Cash Flow
BOKF
BOKF
RPRX
RPRX
Q4 25
$575.2M
Q3 25
$838.5M
Q2 25
$60.8M
Q1 25
$-28.0M
Q4 24
$1.3B
Q3 24
$209.5M
Q2 24
$417.2M
Q1 24
$138.3M
FCF Margin
BOKF
BOKF
RPRX
RPRX
Q4 25
97.6%
Q3 25
152.9%
Q2 25
11.4%
Q1 25
-5.6%
Q4 24
240.7%
Q3 24
40.6%
Q2 24
75.1%
Q1 24
30.4%
Capex Intensity
BOKF
BOKF
RPRX
RPRX
Q4 25
27.9%
Q3 25
5.3%
Q2 25
5.3%
Q1 25
9.6%
Q4 24
32.8%
Q3 24
7.2%
Q2 24
8.3%
Q1 24
9.0%
Cash Conversion
BOKF
BOKF
RPRX
RPRX
Q4 25
4.17×
3.86×
Q3 25
6.16×
2.44×
Q2 25
0.64×
12.06×
Q1 25
0.17×
2.50×
Q4 24
10.51×
3.57×
Q3 24
1.76×
1.29×
Q2 24
2.83×
6.45×
Q1 24
2.14×
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BOKF
BOKF

Segment breakdown not available.

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons